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Abstract
Background: The Sphingosine-1-phosphate (S1P) signaling pathway is known to influence pathophysiological processes
within the brain and the synthetic S1P analog FTY720 has been shown to provide neuroprotection in experimental models
of acute stroke. However, the effects of a manipulation of S1P signaling at later time points after experimental stroke have
not yet been investigated. We examined whether a relatively late initiation of a FTY720 treatment has a positive effect on
long-term neurological outcome with a focus on reactive astrogliosis, synapses and neurotrophic factors.
Methods: We induced photothrombotic stroke (PT) in adult C57BL/6J mice and allowed them to recover for three days.
Starting on post-stroke day 3, mice were treated with FTY720 (1 mg/kg b.i.d.) for 5 days. Behavioral outcome was observed
until day 31 after photothrombosis and periinfarct cortical tissue was analyzed using tandem mass-spectrometry,
TaqManHanalysis and immunofluorescence.
Results: FTY720 treatment results in a significantly better functional outcome persisting up to day 31 after PT. This is
accompanied by a significant decrease in reactive astrogliosis and larger post-synaptic densities as well as changes in the
expression of vascular endothelial growth factor a (VEGF a). Within the periinfarct cortex, S1P is significantly increased
compared to healthy brain tissue.
Conclusion: Besides its known neuroprotective effects in the acute phase of experimental stroke, the initiation of FTY720
treatment in the convalescence period has a positive impact on long-term functional outcome, probably mediated through
reduced astrogliosis, a modulation in synaptic morphology and an increased expression of neurotrophic factors.
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Introduction
Stroke is the leading cause of serious long-term disability in
developed countries. [1] Among stroke survivors, 50% suffer from
a hemiparesis 6 months after stroke. [2] Many clinical trials of
neuroprotective substances failed in the past. Therefore, stroke
prevention and revascularization are still the main therapeutic
options in stroke care. The failure of many experimentally
successful neuroprotective agents in clinical trials may be due to
the fact that many neuroprotectants inhibit not only mechanisms
of damage, but also mechanisms of recovery. [3] FTY720 has
emerged as a promising agent which has shown acute neuropro-
tective properties in different stroke models in mice and rats that
have been reproduced by several independent laboratories. [4,5,6]
However, whether FTY720 also has an effect on long-term
outcome when administered in the remodeling phase starting
several days post-stroke has not yet been studied.
Any damage to the brain leads to transcriptional, biochemical
and morphological changes in astrocytes termed reactive astro-
gliosis. [7] The signaling cues leading to this damage are only
partly known, but appear to be influenced by the cause of damage.
[8] The resulting glial scar is widely considered to have a negative
impact on mechanisms of recovery. [9] However, positive aspects
of reactive astrocytes have also been shown. [10] S1P could be a
direct mediator of reactive gliosis via activation of specific G
protein-coupled S1P receptors, S1PR1–5. [11,12] Some recent
reports suggest that S1P and the S1P receptor agonist FTY720
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and spinal cord injury. [13,14].
We examined whether behavioral recovery could be pharma-
cologically enhanced by delayed administration of FTY720 in a
model of stroke assessing functional outcome over 31 days,
astrocytic reactivity, synaptic morphology and as a possible
mechanism of recovery, the influence of FTY720-treatment on
the expression of neurotrophic factors. We furthermore studied the
concentrations of S1P, FTY720 and phospho-FTY720 (pFTY720)
and the expression levels of key enzymes of S1P metabolism in the
periinfarct cortex.
Methods
Animals and Experimental Model of Photothrombotic
Stroke
Male C57BL/6 mice (6–12 weeks old, strain J) were used in
accordance with the National Institute of Health Guide for the
Care and Use of Laboratory Animals (NIH Publications No. 80-
23, revised 1996). All animal experiments were approved by the
local government authorities (Regierungspraesidium Darmstadt).
Stroke was induced by photothrombosis (PT) as described
previously. [15] Briefly, after injection of buprenorphine, inhala-
tive anesthesia using 2% isoflurane was performed. A cold light
source (KL1500, LCD, Zeiss, Jena, Germany) was connected to a
406 objective, resulting in a 3 mm diameter light beam. The
beam was stereotactically placed 1.5 mm lateral to the bregma. 5
minutes after the injection of 0.2 ml rose-bengal (Sigma-Aldrich,
Taufkirchen, Germany; 10 mg/ml), the scull of the animal was
illuminated for 15 minutes, inducing a focal stroke within the
animal’s right-hemispheric motor cortex. At the indicated time
points, animals were killed using an overdose of isoflurane.
Sample Size Calculation, Experimental Groups and
Randomization Procedure
Sample size calculations for the behavioral analysis as our main
outcome measure were performed using a pilot group of 10
animals analyzed independently of the actual experiments.
Defining an absolute difference of 10% as relevant for the cylinder
task (CT) and 5% in the grid walking test (GWT) and expecting a
standard deviation of 11% in the CT and 5% in the GWT derived
from this pilot study, we calculated the minimal sample size to be
n=19 for the CT and n=16 for the GWT to achieve a statistical
power of 80% with a 0.05 probability of a type I error.
An overview of the experimental groups is given in Table 1.
3 days after PT, mice were randomized using ‘‘pseudorandom’’
numbers (Urbaniak GC, Plous S. Research Randomizer, Version
3.0; 2011. www.randomizer.org; accessed April 22, 2011) and
treatment with i.p. FTY720 (Selleck Chemicals) 1 mg/kg b.i.d. for
5 days versus 0.9% saline was started.
Behavioural Analysis
Analysis of the behavioural outcome after PT was performed as
described previously. [15] The video analysis was done by an
examiner blinded to the treatment groups. The GWT was
performed in a cage with an area of 600 cm
2. The bottom was
replaced by a mesh with an opening width of 1 cm
2. The cage was
placed at a height of 20 cm. A mirror placed under the cage
allowed recording the mice walking on the grid on video for
5 min. The total number of steps was counted, whereas one step is
defined as the movement of all four limbs. Furthermore the foot
faults of the left paretic forepaw were counted. A foot fault is
defined by a limb going through the grid or the paw resting on the
grid only with its wrist.
For the CT, animals were placed in a plexiglas cylinder. While
mice explored the surface by rearing up on their hindlimbs, the
time of wall placement was recorded for the right forelimb, left
forelimb and both forelimbs simultaneously. The difference
between paretic (left) and non-paretic (right) plus bilateral
placement was evaluated for each mouse.
Transcardial Perfusion and Immunohistochemistry
For immunofluorescence, FTY720- and saline-treated mice
(n=6 per group) were sacrificed 7 days after PT. After perfusion
with 0.1 M phosphate buffered saline (PBS), transcardial perfusion
with cold 4% paraformaldehyde (PFA) in 0.1 M PBS was
performed for 20 min, followed by 100 min of postfixation in
4% PFA. 40 mm slides were cut using a vibratome. For
postsynaptic density protein 95 (PSD-95) immunofluorescence, a
permeabilization step with 0.05% Triton X-100 was followed by
preincubation with 10% normal horse serum and 4% Bovine
Serum Albumin. Primary antibodies used here were a mouse anti-
GFAP-Cy3 antibody (Sigma-Aldrich, clone G-A-5) and a rabbit
anti-PSD-95 antibody (Abcam, ab18258), as a secondary antibody
a donkey-anti-rabbit-Alexa488 antibody (Dianova, 711-486-152).
Measurement of Reactive Astrogliosis
All slides of one experiment were incubated within the same
dish, and microscopy performed strictly under the same condi-
tions. We replicated our staining three times. Continuous images
were taken from the entire ipsilateral cortex and arranged using
the ‘‘panorama’’ function of the Axio Vision 4.8 software (Carl
Zeiss, Jena, Germany). Using ImageJ (NIH, Bethesda, Maryland,
USA), a 100 mm
2 grid was projected on the entire image. The
images 100–200 mm from the infarct border and 100–300 mm
Table 1. Experimental groups and number of mice entered into the study.
n of sham-operated mice
n of control mice
(saline=0.9% NaCl)
n of FTY720-treated mice
(1 mg/kg b.i.d. d3 to d7)
Behavioral analysis
observation period 28 days following PT;
assessment at day 7, day 14 and day 28
–2 0 2 0
Immunofluorescence
at day 8 after PT (GFAP, PSD95) – 6 6
Taqman-PCR and lipid tandem mass spectrometry
at day 4 after PT d4 10 d4 10 d4 10
doi:10.1371/journal.pone.0070124.t001
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with ImageJ. After setting the threshold within a replication at the
same grey value, glial fibrillary acidic protein (GFAP)-immunore-
active area was measured using ImageJ.
Measurement of PSD-density and Size
Postsynapticdensityprotein95(PSD95)immunofluorescencewas
performed as previously described. [16] After staining of brain
sections, 16–20 z-stacks of 2 mm thickness of the periinfarct cortex
(100–200 mm from the infarct border and 100–300 mm below the
pia) were taken by a Zeiss confocal microscope, starting 5–10 mm
below the surface of the slide. After deconvolution with the
Richardson-LucyAlgorithm,unimodalthresholdingwasperformed
using matlab (The MathWorks, Natick, Massachusetts, USA). The
Vamp2d plugin was used to visualize synapse size and the vamp3d
dissectionmethodtovisualizesynapsenumber.TheImageJfunction
‘‘particle analyzer’’ was used to do the actualmeasurement.
RT-PCR Analysis
Aftertheindicatedtimepoints,micebraintissuesamplesforPCR
analysiswereexcisedandimmediatelysnap-frozeninliquidnitrogen.
After homogenization for 1 min with 50 Hz using TissueLyser LT
(Qiagen, Hilden, Germany), 1.2 mg of total RNA was isolated with
TRIZOL
TMreagent(Sigma-Aldrich,Steinheim,Germany)accord-
ingtothemanufacture’sprotocolandusedforreversetranscriptase-
polymerase chain reaction (RT-PCR; Revert Aid
TM first strand
cDNA synthesis kit, Thermo Fisher Scientific, St. Leon-Rot.
Germany) utilizing an oligo(dT) primer for amplification.
Real-time PCR (TaqManH) was performed using Applied
Biosystems 7500 Fast Real-Time PCR System. Probes, primers,
andthereporterdyes6-FAMandVICwerefromLifeTechnologies
(Darmstadt, Germany). The cycling conditions were as following:
95uC for 15 min (1 cycle), 95uC for 15 s and 60uC for 1 min (40
cycles). The threshold cycle (Ct) was calculated by the instrument
software(7500FastSystemSDSSoftwareversion1.4).Analysisofthe
relative mRNA expression was performed using the DDCt method.
The housekeepinggene GAPDH was used for normalization.
S1P and FTY720 Quantification by Liquid
Chromatography Tandem Mass Spectrometry (LC/MS/
MS)
For quantification of S1P, FTY720 and its phosphate derivative
FTY720-phosphate (pFTY720) about 10 mg tissue were homog-
enized with PBS and liquid-liquid extracted with methanol:chlor-
oform:HCl (15:83:2). This analytical procedure has been slightly
modified from the method published elsewhere. [17].
Statistical Analysis
All results are displayed as means 6 SD. Statistical significance
was assessed with Student’s two-tailed unpaired t-test for two-
group analyses and one-way ANOVA with Bonferroni correction
for multigroup analyses. Differences with P,0.05 were considered
to be significant.
Results
Delayed Treatment with FTY720 Improves Functional
Neurological Outcome after PT over the Entire
Observation Period of 31 Days
All deaths observed during our study occurred within the first 3
days after surgery, before randomization and we did not need to
exclude animals from our study. Before the operation, mice of
FTY720- and saline-treated groups show the same behavioral
status with an almost zero dexterity result in the CT as well as the
GWT.
At day 7, both tests reveal the extent of the motor cortex lesion,
with all animals showing a stronger use of their ipsilateral limb in
the CT and performing clearly more foot faults in the GWT as
compared to baseline.
Animals treated with FTY720 show a significantly lower deficit
in both tests at day 7. In the CT (Fig. 1a), FTY720-treated mice
show a significantly lower preference of their non-paretic forepaw
as compared to saline-treated mice (FTY720-treated mice:
45.3615.2%, saline-treated mice: 57.5614.2%, P=0.0125,
n=20/group). In the GWT (Fig. 1b), FTY720-treated mice show
significantly lower percentage of foot faults of the paretic forepaw
as compared to saline-treated mice (FTY720-treated mice:
16.863.5%, saline-treated mice: 21.365.4%, P=0.0034, n=20).
This effect persists up to day 31, as reflected in the CT
(29.3611.7% versus 37.167.8%, P=0.0177, n=20) as well as
in the GWT (14.866.2% versus 19.165.7%, P=0.028, n=20).
Figure 1. Improved recovery after stroke with late-initiated
FTY720-treatment. a) Forelimb asymmetry was assessed using the
cylinder task. b) Foot faults were measured using the grid-walking test.
Data are presented as means 6 S.D.; * P,0.05; ** P,0.01; *** P,0.001;
pre-OP - before photothrombotic stroke. Differences between treat-
ment groups at each time point of neurological assessment were
analyzed using Student’s two-tailed unpaired t-test; n=20/group.
doi:10.1371/journal.pone.0070124.g001
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We quantified the GFAP immunoreactivity (2ir) within layer
2/3, at a distance of 100–200 mm from the infarct border, which is
considered to be the main area of axonal sprouting and where
synaptic recovery takes place. [18] Astrocytic reactivity is induced
strongly starting between day 2–3 after PT (data not shown) within
the ipsilateral and the contralateral cortex with a maximal GFAP-
ir at the direct infarct border (Fig. 2a, b). FTY720 treatment
significantly reduces reactive astrogliosis, as measured by the
GFAP-ir area in the indicated periinfarct zone (FTY720-treated
mice: 26.7638.6%, saline-treated mice: 100665.24%, P=0.0395,
n=6; Fig. 2c).
Synapse Size is Increased in FTY720-treated Mice
As an indirect measurement of synaptic morphology within the
periinfarct cortex, the morphology of postsynaptic densities at day
7 was analyzed using the vamping method (Fig. 3a). Within the
selected area, quantified postsynaptic densities are significantly
larger in FTY720-treated animals (338.1647.6 nm) as compared
to the saline-treated animals (257.7647.6 nm, P=0.0152, n=6;
Fig. 3b). The number of postsynaptic densities does not differ
between both treatment groups (FTY720-treated animals:
0.265060.09035 PSD’s/mm
3, saline-treated animals:
0.276860.9979 PSD’s/mm
3, P=0.8838, n=6; Fig. 3c).
FTY720 Treatment Increases the Expression of VEGFa
RT-PCR of the periinfarct tissue was performed in order to
investigate changes in the expression levels of main neurotrophic
factors. FTY720 significantly increases VEGFa-expression at day
4 after PT (Fig. 4). Whereas VEGFa-expression in the periinfarct
cortex is not significantly increased by PT itself (data not shown), it
is significantly higher in FTY720-treated mice (274.16218.5%) as
compared to saline-treated mice (100685.2%, P=0.0305, n=10).
Tissue mRNA levels of erythropoietin (EPO, 108.5688.5% of
saline-treated mice, P=0.8174, n=10) or brain-derived neuro-
trophic factor (BDNF, 103672.64% of saline-treated mice,
P=0.9237, n=10), two other important mediators of CNS
recovery within the periinfarct cortex do not reveal any changes
in the mRNA expression-levels by FTY720-treatment (Fig. 4).
S1P Levels are Increased in the Periinfarct Cortex after PT
In parallel to the therapeutic approach with the S1P analog
FTY720, we investigated changes in concentrations of the natural
signaling molecule S1P within the periinfarct cortex. S1P is
significantly increased at day 4 after PT (343.16275 pg/ml) in
saline-treated animals compared to sham-operated animals
(90.1641 pg/ml, P=0.01, n=10; Fig. 5a). In order to monitor
the pharmacokinetics of FTY720 within the periinfarct cortex in
FTY720-treated animals, we performed tandem mass-spectrom-
etry for FTY720 and pFTY720 one day after the initiation of the
treatment (Fig. 5a). We found that one day of treatment with
1 mg/kg FTY720 b.i.d. leads to a concentration of
10106549.6 pg/ml of FTY720. However, the active metabolite,
pFTY720 had a concentration of 5346427.6 pg/ml (n=10). As
expected, saline treated animals did not show any FTY720 or
pFTY720 in the periinfarct cortex (data not shown).
Enzymes of S1P Metabolism are only Partly Regulated
after Photothrombotic Stroke
RT-PCR of the periinfarct tissue was performed to find changes
in the expression levels of key enzymes of S1P metabolism,
sphingosine kinase 1 (SK1), sphingosine kinase 2 (SK2) and the
S1P-lyase (SGPL1, Fig. 5b). Photothrombotic stroke does not
induce any changes of SK1 (70.5631.5% of sham-treated mice,
P=0.0598, n=10) and SK2 (99.7+96.7% of sham-treated mice,
P=0.9962, n=10) expression. However, SGPL1-mRNA is
significantly increased in the periinfarct cortex (1366.76750% of
sham-treated mice, P=,0.0001, n=10).
Discussion
We show that a short course of treatment with the synthetic
S1P-analog FTY720 from day 3 to day 7 after experimental stroke
enhances functional neurological recovery. This proregenerative
effect of FTY720 is stable over an observation period of 31 days
and accompanied by a reduction of reactive astrogliosis and an
increase in synapse size. As a possible mediator of this effect we
show that FTY720-treatment leads to an increase in the expression
of VEGFa. Furthermore, we demonstrate by means of lipid
tandem mass spectrometry that the tissue S1P concentration rises
in the periinfarct cortex after stroke.
FTY720 treatment improved functional outcome in both the
GWT as well as the CT. Both tests have been widely used to
evaluate long-term neurological deficit in different stroke models.
[19] While the results of the CT reflect an improved motor
recovery in the FTY720 treatment group, the GWT shows that
coordination and sensory function are also improved.
While FTY720 has shown neuroprotective properties in the
acute phase of stroke in several stroke models and animal species,
[4,5,6] this is the first report of enhanced functional recovery
under FTY720-treatment. The relatively late initiation of
FTY720-treatment at day 3 as well as the PT stroke model were
chosen in order to clearly separate a proregenerative effect from
the known acute neuroprotective effect of FTY720. At day 3 after
stroke, further ongoing cell death and increase of infarct size is not
likely. [20,21] Therefore, day 3 is frequently used as a time-point
to initiate neuroregenerative therapies in experimental studies.
Additionally, although PT has been shown to be responsive to
neuroprotectants, [22,23] it is much less responsive than other
stroke models [24,25]. We therefore conclude, that FTY720 might
be one of the very few promising neuroregenerative agents
characterized so far.
As the effect of FTY720 appears to happen prior to day 7, we
anticipated correlative morphological effects at this time point. We
observed that FTY720 also leads to a decrease of reactive
astrogliosis in the periinfarct tissue. The extent of reactive
astrogliosis has been shown to negatively correlate with functional
recovery in various models of neurological disease. [7] Impor-
tantly, FTY720 has been shown to inhibit reactive astrogliosis in
models of multiple sclerosis [13,26] and spinal cord injury [14].
Whether this effect is the result of a direct action of FTY720 at the
astrocyte via S1P-receptors or an indirect mechanism e.g. via
reduced T-cell influx and consecutively reduced cytokine expres-
sion has to be shown in future experiments. The local immune
response seemed not to be influenced by FTY720, as we did not
observe a decreased activation of micoglia/macrophages in the
periinfarct cortex (fig. S1).
Morphological changes in postsynaptic structures are believed
to play a fundamental role in physiological and regenerative
processes. [27,28] PSD size, spine size and the location of AMPA
receptors at the postsynaptic membrane are closely linked and
correlated to synaptic strength. [29,30] The approach used here
has been shown to be a reliable screen for changes in synapse size
and number. [16] Our observation that FTY720 treatment leads
to significant larger PSDs within the area where recovery is
mediated [18] might be an explanation for the improved
FTY720 Enhances Recovery in Photothrombotic Stroke
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e70124Figure 2. FTY720 reduces reactive astrogliosis in the periinfarct cortex. a) GFAP-ir signal in the periinfarct cortex (100–200 mm from infarct
border, denoted by broken line) in saline-treated mice. b) GFAP-ir of reactive astrocytes captured under identical viewing parameters (objective,
exposure time, threshold) in the periinfarct cortex of mice treated for 5 days with FTY720, 1 mg/kg, beginning at day 3. Scale bar=100 mm. c)
Comparison of the GFAP-ir area in the periinfarct cortex of FTY720 and saline treated mice. * P,0.05. Differences between treatment groups were
analysed using the Student’s unpaired two-tailed t-test; n=6/group.
doi:10.1371/journal.pone.0070124.g002
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PSD-density as a probable consequence of an increased axonal
sprouting into the periinfarct cortex.
How could the effect of FTY720 on behavioural and
morphological outcome after photothrombosis be mediated? As
one possible mechanism, we analyzed the mRNA-levels of well-
known neurotrophic factors. Intriguingly, VEGFa mRNA in the
periinfarct cortex is significantly increased by FTY720-treatment.
VEGFa has been shown to enhance synaptic plasticity [31] and to
be beneficial in experimental stroke. [32] Interestingly, VEGFa
has been recently demonstrated to be mainly located within
astrocytes. [33] A pro-angiogenic state has been shown to be
beneficial in stroke patients [34] and, importantly, a late treatment
with VEGFa leads to improved outcome in experimental stroke.
[35] Until now it is a matter of speculation, whether both
increased VEGFa expression and reduced glial reactivity are
results of the same intracellular pathway, modulated by FTY720.
VEGFa expression has been show to be influenced by S1P
signaling in other settings. [36,37] We did not investigate whether
periinfarct angiogenesis is affected by FY720-treatment and
increased VEGFa expression. Interestingly, it should be noted
that FTY720 is discussed as an anti-angiogenic factor. [38] Some
pro-regenerative treatments in experimental stroke have been
shown to be mediated by BDNF [15], and FTY720 was reported
to quickly induce BDNF expression compared to vehicle in a
model of Rett-disease. [39] In contrast, our results argue against a
major impact of a modulated BDNF-expression on the proregen-
erative effect of FTY720 treatment after PT.
Our results from lipid tandem mass spectrometry show a
significant elevation of cortical periinfarct tissue S1P levels after
PT. This is at least in part in line with a previous report, in which
the authors show an increase of S1P in the whole brain at day 14
Figure 3. FTY720-treatment results in larger PSD’s in layer K of the periinfarct cortex. a) Exemplary image of the periinfarct cortex in an
FTY720-treated animal, acquired by confocal microscopy and the vamp2d-algorithm [16]. Scale bar=2 mm. b) Quantification of the PSD-size. c)
Quantification of PSD-numbers by the vamp3d-algorithm. Data are presented as means+S.D. * P#0.05; n.s. - non-significant. Differences between
treatment groups were analyzed using Student’s two-tailed unpaired t-test; n=6/group.
doi:10.1371/journal.pone.0070124.g003
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knowledge, this is the first time that S1P concentrations were
evaluated selectively in the periinfarct cortex with mass spectrom-
etry, the current gold standard method to assess sphingolipid
concentrations. Unfortunately, we were not able to determine the
source of elevated S1P. However, we do not see any hints that the
elevation is a result of a regulated expression of S1P-generating as
well as degenerating enzymes. Only the SGPL1 appears to be
upregulated in the periinfarct tissue, probably as a compensatory
mechanism in order to downregulate the high S1P elevation.
These results do not point to a change in local synthesis of S1P. As
rather high concentrations of S1P can be found intracellularly and
blood plasma, [41] our results might therefore be interpreted as if
the source of increased S1P are either death cells of the infarct core
or the blood-brain barrier damage induced by photothrombosis.
The i.p. injections of FTY720 lead to stable concentrations of
both FTY720 as well as pFTY720 in the periinfarct cortex,
showing an effective activation of FTY720 by sphingosine kinase
2-mediated phosphorylation. [42] pFTY720 has been shown to be
a functional antagonist of S1PR1 and S1PR3 and both receptors
have been discussed to be mediators of astroglial reactivity. [13,43]
It is therefore tempting to speculate that pFTY720 antagonizes the
gliotrophic effect of the elevated S1P concentrations in the
periinfarct tissue.
One has to keep in mind the limitations of the PT model. Major
differences to human stroke are a. the occlusion of all kind of
vessels within the illuminated area, b. the lack of a penumbra and
c. the induction of a vasogenic edema (for review see [44]). As all
these differences particularly affect mechanisms of the develop-
ment of CNS damage, we claim that the model is suitable for the
selective examination of stroke recovery. Unfortunately, transient
proximal middle cerebral artery occlusion for 1 hour was not a
suitable model to confirm our results due to a low seven day
survival and a low deficit of the surviving animals (fig. S2 & S3).
In conclusion, we found that S1P is increased in the periinfarct
cortex after PT with a pronounced motor deficit and that
manipulation of the S1P pathway by FTY720 after the critical
time window for neuroprotection improves long-term outcome
after experimental stroke. In parallel, we observed a reduction of
reactive astrogliosis, alterations in synaptic plasticity and differen-
tial expression of the neurotrophic factor VEGFa. We suggest that
FTY720 is a promising candidate for neuroregenerative therapies
after stroke.
Supporting Information
Figure S1 No difference between treatment groups in
the number of CD11b-ir cells in the periinfarct cortex
after photothrombosis. Results of the immunofluorescence
Figure 4. FTY720-treatment leads to an increase of VEGFa-
mRNA, but not BDNF- and EPO-mRNA in the periinfarct cortex.
RT-PCR analysis of neurotrophic factors in periinfarct tissue of FTY720-
treated mice compared to samples of saline-treated mice. Differences
between treatment groups were analyzed using Student’s unpaired
two-tailed t-test. Data are presented as means+S.D. *, P#0.05; n.s., non-
significant; n=10/group.
doi:10.1371/journal.pone.0070124.g004
Figure 5. S1P is increased in the periinfarct cortex, not
explained by changes in the expression of enzymes of S1P
metabolism. a) S1P, FTY720 and pFTY720 were measured at day 4 by
tandem mass spectrometry. b) SK1, SK2 and SGPL1 were measured at
day 4 by RT-PCR. Differences between treatment groups were analyzed
using Student’s unpaired two-tailed t-test. Data are presented as means
6 S.D. **, P#0.01; *, P#0.05; n.s., non-significant; n=10/group.
doi:10.1371/journal.pone.0070124.g005
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PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e70124analysis, quantified by a rater blinded to treatment groups. Saline-
treated mice: 0.44+0.1 CD11b-ir cells/mm
2; FTY720-treated
mice: 0.35+0.12 CD11b-ir cells/mm
2, P=0.204. Differences
between treatment groups were analyzed using Student’s two-
tailed unpaired t-test; n=6/group.
(TIF)
Figure S2 7-day survival of mice with 1 h tMCAO. 30%
of the operated animals died until day 3, before the start of
randomization and treatment. The red line represents the
beginning of treatment. For comparison, percent survival of the
FTY720-group (dashed line) and saline-group (dotted line) reset to
100%.
(TIF)
Figure S3 No difference of functional deficit between
both treatment groups. a) Results of the cylinder task at day 7
after tMCAO. Saline-treated mice: 24.6+16.8%; FTY-treated
mice: 25.5+12.9%, P=0.925. b) Results of the grid-walking test.
Saline-treated mice: 0.92+1.4%; FTY-treated mice: 1.43+2.6%,
P=0.686. Differences between treatment groups were analyzed
using Student’s two-tailed unpaired t-test; n=5/group.
(TIF)
Methods S1 Supplemental methods.
(DOCX)
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